Staar Surgical Co. (NASDAQ:STAA) was up 2.1% on Thursday . The company traded as high as $9.00 and last traded at $8.95, with a volume of 70,416 shares trading hands. The stock had previously closed at $8.77.

A number of equities research analysts have weighed in on STAA shares. Stephens cut Staar Surgical from an “overweight” rating to an “equal weight” rating in a research note on Thursday, May 12th. Canaccord Genuity reiterated a “hold” rating and issued a $7.00 price objective on shares of Staar Surgical in a research note on Thursday, May 12th. Benchmark Co. upgraded Staar Surgical from a “hold” rating to a “buy” rating and set a $6.00 price objective for the company in a research note on Wednesday, May 18th. Zacks Investment Research upgraded Staar Surgical from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 13th. Finally, William Blair reiterated a “market perform” rating on shares of Staar Surgical in a research note on Thursday, August 4th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Staar Surgical presently has a consensus rating of “Hold” and an average target price of $7.50.

The company’s market capitalization is $359.84 million. The company has a 50 day moving average of $7.50 and a 200-day moving average of $6.80.

Staar Surgical (NASDAQ:STAA) last announced its earnings results on Wednesday, August 3rd. The company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). The company had revenue of $21 million for the quarter, compared to analysts’ expectations of $19.88 million. The company’s quarterly revenue was up 12.4% on a year-over-year basis. On average, equities analysts forecast that Staar Surgical Co. will post ($0.31) EPS for the current fiscal year.

In other Staar Surgical news, major shareholder Broadwood Partners Lp acquired 14,144 shares of the stock in a transaction on Wednesday, June 29th. The stock was purchased at an average price of $5.24 per share, for a total transaction of $74,114.56. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Company operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses (IOLs) used in cataract surgery and implantable collamer lenses (ICLs) used in refractive surgery.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.